Evidence map›Paper›PMID 37107284›Full record

ArticleAntioxidants (Basel, Switzerland)2023

Aldo-Keto Reductase 1C15 Characterization and Protection in Ischemic Brain Injury.

Tuo Yang, Qianqian Li, George Fadoul, Nour Alraqmany, Milos Ikonomovic, Feng Zhang

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tuo YangDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA 15216, USA.ORCID 0000-0002-0418-3014
Qianqian LiDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA 15216, USA.
George FadoulDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA 15216, USA.
Nour AlraqmanyDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA 15216, USA.
Milos IkonomovicDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA 15216, USA.
Feng ZhangDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA 15216, USA.
University of Pittsburgh · US

Funding

Targeting Cerebrovascular Dysfunction for White Matter ProtectionR01NS103810 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI IKONOMOVIC, MILOS D · 2018 to 2022
$2.0M
A novel mechanism of neurovascular protection in ischemic toleranceR01NS092810 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, FENG · 2015 to 2020
$1.7M
NIH HHS NS092810 and NS103810NINDS NIH HHS R01 NS092810NINDS NIH HHS R01 NS103810
6 · The paper itself

Abstract

Aldo-keto reductase (AKR) 1C15, a member of the AKR superfamily, was recently identified and cloned, and reported to alleviate oxidative stress in endothelial cells in rodent lungs. However, its expression and role in the brain and ischemic brain diseases have not been investigated. AKR1C15 expression was detected with real-time PCR. Mouse ischemic stroke and ischemic preconditioning (IPC) were established with middle cerebral artery occlusion (MCAO) for 1 h or 12 min, respectively. Recombinant AKR1C15 was administered intraperitoneally, and stroke outcome was evaluated with neurobehavioral tests and infarct volumes. Rat primary brain cell cultures were subjected to oxygen-glucose deprivation (OGD) to mimic ischemic injury. Cell survival or in vitro blood-brain barrier (BBB) permeability was measured, and nitric oxide (NO) release was detected. Immunostaining and Western blotting were used to evaluate oxidative-stress-related protein expression. AKR1C15 administration decreased the infarct volume and neurological deficits 2d post-stroke, and its early (1-h) administration after IPC abolished the protection of IPC against stroke. In rat primary brain cell cultures, AKR1C15 was most abundantly expressed in brain microvascular endothelial cells (BMVECs) and microglia. Its expression decreased upon OGD in most cell types except for BMVECs and microglia. In primary neuronal cultures, AKR1C15 treatment prevented OGD-induced cell death accompanied by decreased levels of 4-hydroxynonenal, 8-hydroxy-2'-deoxyguanosine, and heme oxygenase-1. In BMVEC cultures, AKR1C15 treatment protected against OGD-induced cell death and in vitro BBB leakage. In primary microglial cultures, AKR1C15 reduced the release of NO upon proinflammatory stimulation. Our results provide a characterization of the novel antioxidant AKR1C15 and demonstrate its protective role against ischemic injury, both in vivo and in vitro. AKR1C15 may be a promising agent for ischemic stroke treatment.

Indexed as

4-hydroxynonenalblood–brain barrierinflammationischemic preconditioningNrf2stroke

Identifiers

PMID37107284
PMCPMC10135333
OpenAlexW4365142034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.